Despite growing appreciation of the importance of long noncoding RNAs (lncRNAs) in normal physiology and disease, our knowledge of cancer-related lncRNAs remains limited. By repurposing microarray probes, we constructed expression profiles of 10,207 lncRNA genes in approximately 1,300 tumors over four different cancer types. Through integrative analysis of the lncRNA expression profiles with clinical outcome and somatic copy-number alterations, we identified lncRNAs that are associated with cancer subtypes and clinical prognosis and predicted those that are potential drivers of cancer progression. We validated our predictions by experimentally confirming prostate cancer cell growth dependence on two newly identified lncRNAs. Our analysis provides a resource of clinically relevant lncRNAs for the development of lncRNA biomarkers and the identification of lncRNA therapeutic targets. It also demonstrates the power of integrating publically available genomic data sets and clinical information for discovering disease-associated lncRNAs.
Despite growing appreciation of the importance of long noncoding RNAs (lncRNAs) in normal physiology and disease, our knowledge of cancer-related lncRNAs remains limited. By repurposing microarray probes, we constructed expression profiles of 10,207 lncRNA genes in approximately 1,300 tumors over four different cancer types. Through integrative analysis of the lncRNA expression profiles with clinical outcome and somatic copy-number alterations, we identified lncRNAs that are associated with cancer subtypes and clinical prognosis and predicted those that are potential drivers of cancer progression. We validated our predictions by experimentally confirming prostate cancer cell growth dependence on two newly identified lncRNAs. Our analysis provides a resource of clinically relevant lncRNAs for the development of lncRNA biomarkers and the identification of lncRNA therapeutic targets. It also demonstrates the power of integrating publically available genomic data sets and clinical information for discovering disease-associated lncRNAs.
Systematic efforts to catalog lncRNAs by traditional cDNA Sanger sequencing 1 , histone mark chromatin immunoprecipitation sequencing (ChIP-seq) 2, 3 or RNA sequencing (RNA-seq) 4, 5 data have revealed that the human genome encodes over 10,000 lncRNAs with little coding capacity. Growing evidence suggests that cancer lncRNAs, similar to protein-coding genes (PCGs), may mediate oncogenic or tumorsuppressing effects and may be a new class of cancer therapeutic targets 6 . Although a handful of lncRNAs have been functionally characterized, little is known about the functions of most lncRNAs in normal physiology or disease 7 . lncRNAs may also serve as cancer diagnostic or prognostic biomarkers that are independent of PCGs. A wellknown example of a potential cancer diagnostic biomarker is PCA3, a prostate-specific lncRNA gene that is markedly overexpressed in prostate cancer. Noninvasive monitoring of urinary PCA3 transcript levels is currently being developed for diagnostics in the clinic 8 .
As lncRNAs do not encode proteins, their functions are closely associated with their transcript abundance. RNA-seq is a comprehensive way to profile lncRNA expression. However, because of the high cost associated with the adoption of this technique, publically available RNA-seq data sets of tumors are relatively limited compared to arraybased expression profiles. In addition, RNA-seq data sets with low sequencing coverage or small sample numbers have only limited statistical power to discover clinically relevant lncRNAs. In contrast, there are a large number of data sets that contain array-based gene expression profiles across hundreds of tumor samples. These array-based expression profiles are often accompanied by matched clinical annotation and/or somatic genomic alteration profiles such as somatic copynumber alterations (SCNAs). Although lncRNAs are not the intended targets of measurement in the original array design, microarray probes can be reannotated for interrogating lncRNA expression [9] [10] [11] [12] [13] [14] . Compared with RNA-seq data of low sequencing coverage, array-based expression data may have lower technical variation and better detection sensitivity for low-abundance transcripts 15, 16 , which is a prominent feature of lncRNAs 5 . Moreover, array-based expression data contain strand information and allow for interrogating the expression of antisense single-exon lncRNAs, whereas most current RNA-seq data in clinical applications do not have strand information and thus are unable to accurately quantify the expression of this class of lncRNAs 17 .
To repurpose the publically available array-based data to interrogate lncRNA expression in tumor samples, we developed a computational pipeline to reannotate the probes that are uniquely mapped to lncRNAs, using the latest annotations of lncRNAs and PCGs. We further performed integrative genomic analyses of lncRNA expression profiles, clinical information and SCNA profiles of tumors in four different cancer types, including 150 tumor samples of prostate cancer from the Memorial Sloan-Kettering Cancer Center (MSKCC) Prostate Oncogenome Project 18 and 451 tumor samples of glioblastoma multiforme (GBM), 585 tumor samples of ovarian cancer (OvCa) and 113 tumor samples of lung squamous cell carcinoma (lung SCC) from the Cancer Genome Atlas Research Network (TCGA) project 19 . We identified lncRNAs that are associated with cancer subtypes or cancer prognosis and predicted those that may have a tumor-promoting or -suppressing function. r e s o u r c e
RESULTS

Repurposing microarray data for probing lncRNA expression
Among the different gene expression microarray platforms, we focused on reannotating the probes from the Affymetrix microarrays. These arrays not only have many more short probes that probably map to lncRNA genes but also are the most widely used platforms for gene expression profiling of patient tumor samples. We designed a computational pipeline to reannotate the probes from five Affymetrix array types (Online Methods and Fig. 1a ) and kept annotated lncRNA and PCG transcripts with at least four probes mapped uniquely to them. Among the five Affymetrix array types, the Affymetrix Human Exon 1.0 ST array has the most comprehensive coverage of the annotated human lncRNAs ( Supplementary Table 1 ). In total, 10,207 lncRNA genes have at least four probes covering their annotated exons ( Fig. 1a) , comprising approximately 64% of all 15,857 lncRNA genes (with over 60% coverage in each category 20 of the lncRNA genes) collected in this study (Online Methods, Fig. 1b,c and Supplementary  Table 2 ). We focused our studies on the Affymetrix exon array expression profiles because of this array's most comprehensive coverage of lncRNAs.
We used a model-based method 21 (Online Methods) to derive the gene expression index of all the PCGs and lncRNAs on exon arrays. To gauge the reliability of our approach, we examined the correlations of both lncRNA and PCG expression between exon array and RNA-seq data that were generated from two different laboratories, using the same prostate cancer cell line, LNCaP 18, 22 . We found that both PCGs (r = 0.70, P < 2.2 × 10 −16 ) and lncRNAs (r = 0.29, P < 2.2 × 10 −16 ) showed significant concordance of expression between the exon array and RNA-seq data ( Supplementary Fig. 1a,b ). This observation is consistent with the previous finding that the correlation between microarray and RNA-seq data is lower in genes with low expression 23 , as lncRNAs are generally expressed at lower levels than PCGs 5 . As the level of probe coverage could also influence the accuracy of lncRNA expression derived from a microarray, we further investigated how the correlations of expression between the exon array and RNA-seq data change at different probe coverages by examining those PCGs with expression levels similar to those of lncRNAs ( Supplementary  Fig. 1c ). We found that the correlation between exon array-and RNAseq-based expression showed a moderate increase when all probes (0.28) were used as compared with when only four probes (0.20) were used ( Supplementary Fig. 1c ). The correlations were similar for PCGs (0.28) and lncRNAs (0.29) when we controlled for expression level. These results suggest that although probe coverage may influence the array-based lncRNA expression estimation, the dominant factor that governs the observed difference in correlation between array and RNA-seq data for PCGs and lncRNAs is their expression level. A recent study, in which a 60-mer custom oligonucleotide array was designed to investigate lncRNA expression, showed that the correlation of lncRNA expression between the custom array and RNA-seq data was between 0.24 and 0. 31 (ref. 20) . Therefore, although the concordance between exon array and RNAseq data is lower for lncRNA expression than for PCG expression, it may represent the typical performance in comparison of lncRNA expression between an array-based platform and RNA-seq.
lncRNAs associated with cancer status, subtype and prognosis
To validate the utility of exon array data in combination with clinical annotation to identify cancer-related lncRNAs, we examined the expression patterns of 13 literature-curated cancer-related lncRNAs 6 that have corresponding exon array probes in a prostate cancer data set 18 . This data set consists of 29 normal prostate samples, 131 primary prostate tumor samples and 19 metastatic prostate tumor samples with exon array data 18 (Fig. 2a) . Notably, 9 out of these 13 known cancerrelated lncRNAs showed significantly different expression between the tumor and normal prostate samples (Mann-Whitney U (MWU) test, P < 0.05). Three out of these nine lncRNAs were directly related to prostate cancer, including one known prostate cancer diagnostic biomarker, PCA3 (ref. 8) , and two lncRNAs, PCAT-1 (ref. 22 ) and PCGEM1 (ref. 24) , that have been functionally implicated in prostate cancer progression. GAS5, a tumor-suppressive lncRNA known to be downregulated in breast cancer 25 , showed increased expression in prostate cancer ( Table 1) , a result suggesting complex and contextdependent functions of lncRNAs in different cancer types. Notably, several lncRNAs, such as NEAT1 (ref. 26 ), DANCR 27 , HOTTIP 28 , PRINS 29 and EGOT 30 , that have established functions in forming nuclear speckles 26 , in development 27 and in autoimmune disease 29 but were not previously known to be related to cancer showed differential expression between tumor and normal prostate samples ( Table 1) , and this suggests their potential function in prostate cancer.
We next sought to identify lncRNAs that showed significant expression differences between tumors and normal prostate tissues and found 109 upregulated and 104 downregulated lncRNAs (MWU test, false discovery rate (FDR) < 0.05, fold change ≥1.5) ( Fig. 2a) . Notably, among the lncRNAs with sufficient exon array probe coverage, we rediscovered seven out of eight lncRNAs that were reported to show higher expression in prostate cancer from an independent study based on RNA-seq data 22 . Furthermore, we identified an additional 102 lncRNA genes that were upregulated in prostate cancer but were missed by the other study 22 , and this suggests that arrays and RNA-seq may be complementary methods to identify clinically relevant lncRNAs. When a lncRNA acts in cis and influences the expression of its neighboring PCG, or a lncRNA and its neighboring PCG are under the same cis regulation, they can show coordinated expressions. We compared the distribution of the correlation between a lncRNA and its neighboring PCG from different lncRNA classes ( Supplementary Table 2 ). 5 Notably, antisense genic lncRNAs were slightly better correlated with their sense PCG than were intergenic lncRNAs (P < 10 −10 ) ( Supplementary Fig. 2a,b) , a result suggesting more coordinated expression between a sense PCG and an antisense lncRNA gene. Cancer is a clinically heterogeneous disease, and individual cancer types can be further divided into molecular subtypes, each with specific biological and clinical behaviors. Previous studies established four subtypes of GBM (proneural, neural, classical and mesenchymal) 19 , four subtypes of OvCa (immunoreactive, proliferative, mesenchymal and differentiated) 31 , four subtypes of lung SCC (basal, classical, primitive and secretory) 32 on the basis of the expression profiles of PCGs and six subtypes of prostate cancer on the basis of the SCNA profiles 18 .
lncRNAs with subtype-specific expression may have an important function in individual molecular subtypes. We compared lncRNA expression across different subtypes (Online Methods) and identified hundreds of lncRNAs showing significant subtype-specific expression patterns in GBM, OvCa and lung SCC (FDR < 0.05; Fig. 2b-e ). The same approach did not yield any lncRNAs with significant subtypespecific expression in prostate cancer, which was reminiscent of the lack of a robust PCG expression-based subtype of prostate cancer 18 . In addition, 628 lncRNAs showed subtype-specific expression in more than one cancer type (Fig. 2b) , and some of these lncRNAs have been functionally implicated in other physiological or pathological processes. For example, MIAT, a lncRNA that showed specific expression in the mesenchymal subtype of OvCa and the proneural subtype of GBM, is known to confer risk of myocardial infarction 33 and regulate retinal cell fate specification 34 . In addition, RMST, a lncRNA known to be differentially expressed between rhabdomyosarcoma subtypes 35 , also showed subtype-specific expression patterns in GBM, OvCa and lung SCC.
A previous study of HOTAIR 36, 37 showed that patients with higher HOTAIR expression had poorer prognosis in colorectal cancer 38 . To identify the lncRNAs that are associated with clinical outcome in prostate cancer, GBM, OvCa and lung SCC, we performed multivariate Cox regression analysis to evaluate the significance of the correlations between individual lncRNA expression and overall and progression-free survival in the presence of other confounding factors npg r e s o u r c e such as ethnicity, age and gender (Online Methods). We identified approximately 100 lncRNAs each in prostate cancer, GBM, OvCa and lung SCC whose expression was markedly correlated with overall or progression-free survival ( Supplementary Table 3 ). Notably, nine lncRNAs showed consistent positive or negative correlations between their expression and overall or progression-free survival in different cancer types, and this suggests their potential as more general prognostic biomarkers. The lncRNA gene with the Ensembl ID ENSG00000261582 is an example of a lncRNA that showed negative correlation between its expression and overall survival in both lung SCC and OvCa (Fig. 3a) . This lncRNA also showed subtype-specific expression in OvCa but not in lung SCC. Additionally, five lncRNAs showed marked and consistent positive or negative correlations between both overall and progression-free survival in OvCa (one such example, Ensembl ID ENSG00000225128, is shown in Fig. 3b ).
Predicting lncRNAs that are potential cancer drivers
An important form of somatic genetic alteration in cancer is SCNAs, in which a genomic region is either amplified or deleted. Some of the genes within amplified (or deleted) regions show increased (or decreased) expression levels leading to altered activity in cancer cells. Studies have suggested that the genes with causal roles in oncogenesis are often located in the SCNAs that are frequently altered across tumors 39, 40 . To reveal the lncRNAs that may have tumor-promoting or -suppressing functions, we identified hundreds of lncRNAs that map to regions of recurrent SCNAs across tumors (Online Methods) for prostate cancer, GBM, OvCa and lung SCC (Fig. 3c) . Some of these lncRNAs also showed marked correlation between overall or progression-free survival ( Supplementary Table 4 ). In addition, we identified lncRNAs that were consistently located in regions of SCNAs across different cancers ( Fig. 3c) and found a significant overlap of the lncRNA genes that are located in SCNA gain or loss regions between some of the cancer types ( Supplementary Table 5 ).
Among the many genes located within regions of SCNAs, probably only a fraction of them are drivers of cancer. To further distinguish driver from passenger lncRNAs in the regions of SCNAs, we integrated SCNA and expression profiles of lncRNAs in tumors. We reasoned that driver lncRNAs with SCNAs should result in corresponding gene expression changes 40, 41 , as only those SCNAs that cause changes in transcript abundance could possibly alter lncRNA activity. Therefore, we selected lncRNAs whose SCNAs showed positive correlations with expression level changes as candidate drivers (Online Methods and Supplementary  Table 3 ) for prostate cancer, GBM, OvCa and lung SCC. 
Experimental validation of two new lncRNAs
As it is prohibitive to validate all candidate driver lncRNAs in the four cancer types, we focused our experimental validation on candidate lncRNAs that may have tumor-promoting functions in prostate cancer (that is, those in recurrent SCNA (gain) regions that showed positive correlations between their SCNAs and expression levels). Among all the candidate driver lncRNAs that showed increasing expression from normal to primary to metastatic prostate cancer, we chose the two that showed the most significant expression difference between tumor and normal prostate tissue (that is, the two with the smallest P values calculated by MWU test) for experimental validation. We named these two lncRNAs prostate cancerassociated noncoding RNAs 1 and 2, abbreviated as PCAN-R1 (Ensembl ID ENSG00000228288) and PCAN-R2 (Ensembl ID ENSG00000231806), respectively. The criterion of increasing expression from normal to primary to metastatic prostate cancer aimed to uncover lncRNAs that may be important therapeutic targets for both primary and metastatic cancers (Fig. 4a) . Both PCAN-R1 and PCAN-R2 showed a positive correlation between gene expression and SCNA ( Fig. 4b and Supplementary Fig. 3a) . Coding-potential analysis confirmed the noncoding nature of these two lncRNAs (Online Methods). We chose the prostate cancer cell line LNCaP, in which both lncRNAs have moderate or higher expression levels compared with their expression in other prostate cancer or non-prostate cancer cell lines, for experimental validation (Supplementary Fig. 3b,c) . Using 5′ and 3′ rapid amplification of cDNA ends (RACE), we found that for PCAN-R1, although one isoform (PCAN-R1-A) was almost identical to the Ensembl annotated transcript ENST00000425295 ( Fig. 4c  and Supplementary Fig. 4a) , the other isoform (PCAN-R1-B) was a spliced variant of PCAN-R1-A with an intron retention (Fig. 4c) .
Notably, for PCAN-R2, the major isoform had an extra exon in the 5′ end, and the remaining two exons also had different lengths from the Ensembl annotation ( Fig. 4c and Supplementary Fig. 4b) .
The new 5′ exon of PCAN-R2 was more consistent with the profile of histone H3 Lys4 trimethylation (H3K4me3), a histone mark of an active promoter and the profile of DNase I hypersensitive regions (that is, the regions with an open chromatin state) in LNCaP cells. We further confirmed the transcript structures of PCAN-R1 and PCAN-R2 by northern blot (Online Methods and Fig. 5a ).
On the basis of the determined lncRNA transcript structures, we designed short interfering RNAs (siRNAs) that targeted the common exon of each lncRNA gene. Notably, knockdown of either PCAN-R1 or PCAN-R2 by two different siRNAs each (Fig. 5b) resulted in substantial decreases in both cell growth ( Fig. 5c ) and soft-agar colony formation in the androgen-dependent prostate cancer cell line LNCaP (Fig. 5d) . We further confirmed this growth inhibition after lncRNA knockdown in the androgen-independent prostate cancer cell line LNCaP-abl (Supplementary Fig. 5a,b) . To rule out the possibility that the observed phenotypes were from an off-target effect of the siRNA on PCG expression, we searched the homologous sequences of the designed siRNA sequences in all protein-coding transcripts. We found no hits with the perfect match or one mismatch and only five transcripts from five genes for all the siRNAs when two mismatches were allowed. Among these, two PCGs, MYSM1 (potentially targeted by the PCAN-R1-specific siRNA siR1-1) and ADAMTS17 (potentially targeted by the PCAN-R2-specific siRNA siR2-2) showed elevated expression in prostate tumors compared to in normal samples, results that resembled those of PCAN-R1 and PCAN-R2 in terms of expression pattern and indicated their potentials of functionality accordingly. The expression of these two genes was unaffected by treatment with their corresponding siRNAs, and this suggests that the observed cellular phenotype of the selected lncRNAs after knockdown by siRNA was probably not from an off-target effect on PCGs (Supplementary Fig. 5c,d) .
As a lncRNA may act in cis and influence the expression of its neighboring PCG, we investigated whether the expression of the neighboring PCG was regulated by PCAN-R1 or PCAN-R2. siRNA knockdown of PCAN-R1 or PCAN-R2 had no effect on the expression of their neighboring PCGs KDM5B and FBP2 (Supplementary Fig. 5c,d) , respectively, and this suggests that the functional mechanisms of PCAN-R1 and PCAN-R2 are not directly through their neighboring PCGs. Notably, in normal tissues, PCAN-R1 and its neighboring PCG KDM5B showed the highest expression in testis ( Supplementary Fig. 5e,f) . In contrast, although PCAN-R2 showed similar expression across different tissues, its neighboring PCG FBP2 showed a muscle-specific expression pattern (Supplementary Fig. 5e,f) , thus suggesting that the expressions of PCAN-R2 and FBP2 may be differently regulated.
DISCUSSION
Our analyses demonstrate that repurposing microarray probes to construct a lncRNA expression profile in a patient sample is a costeffective approach given the large number of such data sets available in public repositories. The constructed gene expression profiles of both lncRNAs and PCGs from our analyses are a valuable resource for understanding the similarities and differences of transcriptional (for example, antisense RNA 42 ) regulation of PCGs by lncRNAs across different cancer types. In the combination of matched SCNA profile and clinical information, these gene expression profiles also allow network models to be inferred 43, 44 , which will help advance the understanding of lncRNA function in cancer etiology.
More importantly, the experimental validation of two lncRNAs without previous implication in cancer suggests the effectiveness of npg r e s o u r c e our integrative analyses in finding functionally important lncRNAs in cancer. Our analyses predicted about 80-300 candidate driver lncRNAs that may have tumor-promoting functions in each of the four cancer types. An intersection of such a list of candidate driver lncRNAs with a list of lncRNAs generated from orthogonal functional genomic data sets, such as that generated by ribonucleoprotein immunoprecipitation followed by sequencing 45 (a genomic technique for identifying lncRNAs physically associated with the protein of interest), would greatly help prioritize their functional valuation in different biological contexts, including epigenetic regulation, and facilitate the discovery of lncRNA therapeutic targets.
In our current study, we only used SCNA and expression data in combination with clinical information for our integrative analysis. It is conceivable that other types of genomic data such as SNP array 46 and genome sequencing data 47 can be further integrated to reveal the multifaceted relationship between the mutation spectrum and expression of lncRNAs, disease status and clinical outcome.
In summary, we report a proof-of-principle study for identifying clinically relevant lncRNAs through integrative analyses of orthogonal genomic data sets and clinical information. Our study opens new avenues for leveraging publicly available genomic data to study the functions and mechanisms of lncRNAs in human diseases.
METhODS
Methods and any associated references are available in the online version of the paper.
ONLINE METhODS
Repurposing data from the Affymetrix Human Exon 1.0 ST array and Affymetrix 3′ IVT arrays to interrogate lncRNA expression. We collected lncRNA annotations from two sources: the catalog of lncRNAs from the Ensembl database 48 (Homo sapiens GRCh37, release 67) and the catalog of lncRNAs generated on the basis of transcriptome assembly from RNA-seq data 5 . For those lncRNA transcripts with overlap on the same strand between these two sources, we only kept the Ensembl annotation (Fig. 1a) to avoid redundancy. This resulted in a total of 15,857 lncRNA genes. We reannotated probe sets of the Human Exon array for lncRNAs by mapping all probes to the human genome (hg19) by using SeqMap 49 . We kept those probes that mapped uniquely to the genome with no mismatch. We then removed all probes that mapped to proteincoding transcripts (183,252) or pseudogene transcripts (15, 789) on the basis of the annotations from the Ensembl 48 (http://www.ensembl.org/) and UCSC 50 (http:// www.genome.ucsc.edu/) databases. By matching the rest of the probes to lncRNA sequences, we obtained 202,449 probes and 10,207 corresponding lncRNA genes with at least four probes. The same strategy was applied to generate the probes that corresponded to lncRNA transcripts for the other 3′ IVT Affymetrix array platforms. The raw intensity of the exon array probes was corrected with a probe sequence-specific background model, and the expression level of a lncRNA gene was calculated by summarizing the background-corrected intensity of all probes corresponding to this gene 21 . The lncRNA expression was quantile normalized across different biological samples. The gene expression calculation was implemented with Jetta 51 . When batch information was available, Combat 52 , an empirical Bayes method, was used to remove potential batch effects. lncRNA classification. The lncRNA classification scheme was adopted from a previous study 20 . The lncRNAs were categorized as intergenic or genic. The neighboring PCGs of lncRNAs were selected on the basis of either the nearest distance to the lncRNA or the longest overlapping regions. The intergenic lncRNAs were subclassified as 'same strand' , 'convergent' or 'divergent' according to their relative orientation with the neighboring PCGs. The genic lncRNAs were classified as being exonic, intronic or overlapping and sense or antisense according to their relation with neighboring PCGs. The classification of all lncRNA genes with at least four exon array probes are available at http://compbio.tongji. edu.cn/~duz/lncRNA/lncRNA_data_repository.html.
Comparative analysis of exon array and RNA-seq data. We obtained RNA-seq 22 and exon array 18 data for the LNCaP cell line from two different studies 18, 22 . RNA-seq-based gene expression was calculated with Cufflinks1.0.2 (ref. 53) (default parameters and the -G option), and the exon array-based gene expression was calculated by the same procedure as was described in the first section of the Online Methods. The Pearson correlation coefficient was used to quantify the strength of the associations between the exon array-based and RNA-seq-based expression levels.
Exon array data, clinical annotation and SCNA data of different cancers. For prostate cancer, we obtained exon array data, clinical annotation and SCNA data generated by the MSKCC Prostate Oncogenome Project 18 from the Gene expression Omnibus (GEO) (GSE21034). This data set included 29 normal adjacent, 131 primary and 19 metastatic tissue specimens, as well as four prostate cell lines, with exon array data. The exon array data, clinical annotations and SCNA data of 451 GBM 19 , 585 OvCa 31 and 113 lung SCC 32 primary tumors were downloaded from TCGA (https://tcga-data.nci.nih.gov/). We further obtained exon array data of 11 human normal tissues from Affymetrix (http://www.affymetrix.com/). The processed array-based expression and the corresponding SCNA of lncRNA genes with at least four exon array probes are available at http://compbio.tongji.edu. cn/~duz/lncRNA/lncRNA_data_repository.html.
Identifying lncRNAs associated with overall and progression-free survival or cancer subtype. We performed multivariate Cox proportional hazard (Cox regression) analyses to assess the associations between different covariates, including lncRNA expression, ethnicity, age and gender, with overall and progressionfree survival. In addition to lncRNA expression, we included clinical outcome and covariate data that were available in the individual data sets for analysis. For GBM and lung SCC, we included ethnicity, age and gender, whereas for prostate cancer and OvCa, we included only ethnicity and age as additional covariates.
The Cox regression analyses were performed for overall survival in GBM and lung SCC, for progression-free survival in prostate cancer and for both overall and progression-free survival in OvCa. Molecular subtype information for 220, 487, 89 and 150 tumor samples from GBM, OvCa, lung SCC and prostate cancer, respectively, were obtained from previous studies 18, 19, 31, 32 . One-tailed MWU test was performed to compare lncRNA expression in each subtype to those in other subtypes in the same cancer. The lncRNAs that showed statistically higher expression (FDR < 0.05) in only one subtype were considered to be subtype specific. The list of lncRNA genes, the expression of which were associated with overall and progression-free survival or cancer subtype, are available at http://compbio. tongji.edu.cn/~duz/lncRNA/lncRNA_data_repository.html.
Identifying candidate driver lncRNAs by integrating SCNA and expression data. The recurrent SCNA regions of prostate cancer, GBM, OvCa and lung SCC were identified by the GISTIC 54, 55 or RAE 56 algorithm in previous studies 19, 31, 32 . For prostate cancer, the SCNA regions were determined as the union of SCNA regions from two different studies 18, 39 . The magnitude of the SCNAs was estimated as the log2 ratios of segmented copy numbers between cancer and control DNAs. Among the lncRNAs in the SCNA regions, we selected those that showed significant and concordant expression changes (one-tailed MWU test, P < 0.05) in tumor samples with a corresponding somatic copynumber gain (log2 ratio > 0.2) or loss (log2 ratio < −0.2) compared to the other samples (Supplementary Table 2 ). The list of predicted candidate driver lncRNAs is available at http://compbio.tongji.edu.cn/~duz/lncRNA/lncRNA_ data_repository.html.
Coding potential analysis. To confirm that the two lncRNAs PCAN-R1 and PCAN-R2 are noncoding, we used two different methods, txCdsPredict from UCSC and phyloCSF 57 , to calculate their coding potential. For coding-potential calculations with phyloCSF, we used the multiple sequence alignment of 29 mammalian genomes 58 . We chose the thresholds used previously (txCdsPredict = 800 (ref. 22 ) and phyloCSF = 100 (ref. 5)), below which the transcripts were considered to be noncoding. We found that the scores of all possible opening reading frames from the PCAN-R1 and PCAN-R2 transcripts were well below the thresholds (txCdsPredict scores: PCAN-R1, 470 and PCAN-R2, 359; phyloCSF scores: PCAN-R1, −123.1434 and PCAN-R2, −148.5448), supporting that these two lncRNA genes are noncoding.
Cell culture. LNCaP, CWR22Rv1 and PC3 cells were cultured in RPMI 1640 medium supplemented with 10% FBS. LNCaP-abl and LNCaP-AI cells were maintained in phenol red-free RPMI 1640 medium with 10% charcoal-and dextran-treated FBS. VCaP, HeLa and 293T cells were grown in DMEM with 10% FBS.
Quantitative RT-PCR analysis. RNA was isolated with the RNeasy Mini Kit (Qiagen). Reverse transcriptase (Invitrogen) was used for randomprimed first-strand cDNA synthesis. Real-time PCR was carried out on an ABI Prism 7300 detection system with SYBR Green PCR master mix. The ∆∆Ct method was used to comparatively quantify the levels of mRNA. RPS28 gene expression served as the internal control. The primer sequences used were: RPS28, 5′-CGATCCATCATCCGCAATG-3′ (forward) and 5′-AGCCAAGCTCAGCGCAAC-3′ (reverse); PCAN-R1, 5′-CA GGAACCCCCTCCTTACTC-3′ (forward) and 5′-CTAGGGATGTGTCCG AAGGA-3′ (reverse); PCAN-R2, 5′-CTTGGCTGTGGTCACTCTGA-3′ (forward) and 5′-ACACACAGTTGGGTTCACCA-3′ (reverse); KDM5B, 5′-ATTGC CTCAAAGGAATTTGGCAGTG-3′ (forward) and 5′-CATCACTGGCATGTTG TTCAAATTC-3′ (reverse); MYSM1, 5′-CAAATCAGAAGACCGGCCATAA-3′ (forward) and 5′-GCACGTCCCCTTAAACATGATG-3′ (reverse); FBP2, 5′-GG GTCAAGCATGAAGAGGTC-3′ (forward) and 5′-CAGAGGATGAGCCT TCTGAAA-3′ (reverse); and ADAMTS17, 5′-ACGACAACGTCCCGCTAAG-3′ (forward) and 5′-TCCTCCATACTCCTCGTTCTG-3′ (reverse). RACE and northern blot analysis. 5′ and 3′ RACE were performed with the RLM-RACE Kit (Ambion) following the manufacturer's manual. Northern blot analyses were performed with the DIG (digoxigenin) Northern Starter Kit (Roche). DIG-labeled RNA probes were generated by in vitro transcription with T7 RNA polymerase from the PCR products of the corresponding npg regions to detect specific lncRNA transcripts in poly(A)-enriched mRNAs of LNCaP cells. The PCR primers used to amplify specific regions for northern probes were: PCAN-R1, 5′-GACCTGGGCAACCCCAGCCTG-3′ (sense) and 5′-GATCACTAATACGACTCACTATAGGGCGCGAGGAGCGCCTCA TCACC-3′ (antisense, including the T7 promoter sequence); and PCAN-R2, 5′-GACAAATTCACCAAGAGCCTAG-3′ (sense) and 5′-GATCACTAATACGA CTCACTATAGGGGAAGACTATGGGCTGCTTCCTT-3′ (antisense, including the T7 promoter sequence).
RNA interference. The siRNA oligonucleotides were synthesized by Dharmacon, Inc. The target sequences were as follows: siCtrl, 5′-GCGACCAACGCCTTGA TTG-3′; siR1-1, 5′-GGTGTCTCCATCCTCATTC-3′; siR1-2, 5′-CTCCCAGA CCTCACGTCAA-3′; siR2-1, 5′-ACAGGAAGCTCTAGCAGTA-3′; and siR2-2, 5′-CCATCAACAGTGAGAGGAA-3′. Cells were transfected with 20 nM siRNA oligonucleotides and RNAiMax reagent (Invitrogen) in 24-well plates. The knockdown efficiency was determined by quantitative RT-PCR at 48-72 h after transfection.
Cell growth and soft agar assay. For cell growth assays, cells were plated in 24-well plates, transfected with the indicated siRNA oligonucleotides in triplicate and allowed to grow for another 5 d. Cells were counted every other day with a hemocytometer. Anchorage-independent cell growth in soft agar was performed in triplicate with 10,000 LNCaP cells per well suspended in 1.5 ml of medium containing 0.35% agar spread on top of 1.5 ml of 0.7% solidified agar in six-well plates.
Colonies were stained with crystal violet and counted after 4 weeks of plating. Data are shown as the mean ± s.d. n = 3 biological replicates.
